Research programme: monoclonal antibody biosimilars - TOT Biopharm

Drug Profile

Research programme: monoclonal antibody biosimilars - TOT Biopharm

Alternative Names: BCIA07; TAA013; TAB 014; TAD 011; TAT014; TOT104

Latest Information Update: 09 Jan 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TOT Biopharm
  • Developer Lees Pharmaceutical Holdings; TOT Biopharm
  • Class Antineoplastics; Eye disorder therapies; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Mantle-cell lymphoma; Solid tumours; Wet age-related macular degeneration

Most Recent Events

  • 09 Jan 2017 TOT Biopharm files an IND application with the CFDA in China
  • 05 Jan 2017 TAB 014 licensed to Lees Pharmaceutical Holdings in China, Hong Kong and Macau
  • 05 Jan 2017 Early research in Wet age-related macular degeneration in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top